C12N 2760/18741
Use of virus, viral particle or viral elements as a vector
C12N2760/18741 (Use of virus, viral particle or viral elements as a vector) appears on 22 US grants and 37 published applications in this corpus.
Search patents in C12N- Granted patents
- 22
- Published applications
- 37
- Assignees
- 22
- Inventors
- 46
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 2 |
| 2008 | 1 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 0 | 2 |
| 2015 | 1 | 2 |
| 2016 | 1 | 0 |
| 2017 | 3 | 3 |
| 2018 | 0 | 3 |
| 2019 | 1 | 2 |
| 2020 | 3 | 2 |
| 2021 | 2 | 3 |
| 2022 | 0 | 1 |
| 2023 | 3 | 2 |
| 2024 | 2 | 3 |
| 2025 | 1 | 3 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/18743Viral genome or elements thereof as genetic vectorIndexing code20
- C12N 2760/18745Special targeting system for viral vectorsIndexing code2
- C12N 2760/18742Virus or viral particle as vehicleIndexing code1
- C12N 2760/18744Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
Recent patents
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/PIV3 F protein and uses thereof2 Jun 2026US 12,643,925 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells27 May 2025US 12,312,393 B2University of Central Florida Research Foundation, Inc.
- Compositions and methods for differentiation of human pluripotent stem cells into desired cell types24 Sep 2024US 12,098,392 B2Elixirgen Scientific, Inc.
- Recombinant human parainfluenza virus type 1 expressing a chimeric RSV/HPIV1 f protein and uses thereof25 Jun 2024US 12,018,051 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells27 Jun 2023US 11,684,637 B2University of Central Florida Research Foundation, Inc.
- Anticancer agent, pharmaceutical composition for cancer treatment, kit, and activator20 Aug 2026US 2026/0240929 A1BioComo Incorporation
- Piv5-based covid-19 vaccine12 Mar 2026US 2026/0069674 A9University of Georgia Research Foundation, Inc.
- Piv5-based covid-19 vaccine16 Oct 2025US 2025/0319176 A1University of Georgia Research Foundation, Inc.
- Viral vectors3 Jul 2025US 2025/0213674 A1City, University of London
- Compositions And Methods For Differentiation Of Human Pluripotent Stem Cells Into Desired Cell Types23 Jan 2025US 2025/0027054 A1Elixirgen Scientific, Inc.
Most cited
By later US patents
- Rescue of mumps virus from cDNA5US 7,361,496 B1Wyeth · 2008
- Recovery of recombinant human parainfluenza virus type 2 (HYPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens4US 8,367,074 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2013
- Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof2US 11,591,372 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2023
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof1US 10,654,898 B2The United States of America, as represented by the Secretary, Department of Health and Human Serices · 2020
- Parainfluenza virus 5 based vaccines1US 10,752,916 B2University of Georgia Research Foundation, Inc. · 2020